Company Overview
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.08.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -37.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -37.70% |
Stock Price Performance
| 1 Year: | +53.39% |
| 6 Months: | -72.80% |
| 3 Months: | -74.96% |
| 1 Month: | -7.00% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)33.62 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 77.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ALMS Alumis Inc. R2KR3KPHARMA | 6.78 | -1.76 | $877.57M | 0.00% | -134.01% | -93.65% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 17.39M | 2.67M | 2.07M | 1.93M | 1.74M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | 118.92M | 143.21M | 117.36M | 98.37M | 100.15M |
| Operating Income | - | -37.62M | -43.76M | -47.59M | -56.14M | - | - | -101.53M | -140.54M | -115.29M | -96.44M | -98.41M |
| EBITDA | - | - | - | - | - | - | - | -100.69M | -139.67M | -114.38M | -95.58M | -97.54M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | -98.96M | 50.76M | -110.75M | -92.93M | -93.05M |
| Tax Provision | - | - | - | - | - | 0 | - | - | -8.56M | 0 | 0 | - |
| Net Income | -36.03M | -36.29M | -43.38M | -49.85M | -56.51M | - | - | -98.96M | 59.32M | -110.75M | -92.93M | -93.05M |
| Diluted EPS | - | -17.13 | -19.76 | -21.03 | -23.10 | -1.73 | - | -1.82 | 0.57 | -1.06 | - | -0.74 |
| R&D Expense | - | 32.85M | 37.79M | 41.96M | 48.56M | 87.82M | - | 96.62M | 108.75M | 97.84M | - | 81.54M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 24.05M |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 113.85M | 158.17M | 300.75M | 477.85M |
| Operating Income | -113.85M | -158.17M | -300.75M | -453.80M |
| EBITDA | -113.60M | -156.89M | -297.60M | -450.31M |
| Interest Expense | - | - | - | - |
| Pretax Income | -111.93M | -154.99M | -294.23M | -251.89M |
| Tax Provision | - | - | 0 | -8.56M |
| Net Income | -111.93M | -154.99M | -294.23M | -243.32M |
| Diluted EPS | -2.91 | -2.99 | -10.38 | -2.32 |
| R&D Expense | - | 137.68M | 265.55M | 386.00M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | 108.17M | 89.61M | 340.99M | 411.94M |
| Current Assets | 102.56M | 53.36M | 306.19M | 318.23M |
| Cash & Equivalents | 25.61M | 46.00M | 169.53M | 89.67M |
| Inventory | - | - | - | - |
| Receivables | 500.00K | 722.00K | 1.81M | 2.08M |
| Total Liabilities | 303.41M | 428.87M | 80.89M | 110.64M |
| Current Liabilities | 13.35M | 20.87M | 50.91M | 73.32M |
| Long Term Debt | - | - | - | - |
| Total Debt | 1.78M | 32.58M | 30.72M | 36.91M |
| Total Equity | -195.24M | -339.26M | 260.10M | 301.30M |
| Shares Outstanding | 51.84M | 51.84M | 54.41M | 104.71M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -107.72M | -129.97M | -255.08M | -369.52M |
| Investing Cash Flow | -68.75M | 60.47M | -113.79M | 287.88M |
| Financing Cash Flow | 101.63M | 89.68M | 492.37M | 2.07M |
| Capital Expenditure | -2.41M | -4.50M | -1.73M | -653.00K |
| Free Cash Flow | -110.13M | -134.47M | -256.81M | -370.18M |
| Net Change in Cash | -74.85M | 20.18M | 123.50M | -79.58M |
| Share Buybacks | - | 64.00K | 6.00K | 17.00K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | -1,886.9% |
| Net Margin % | - | - | - | -1,011.7% |
| ROE % | 57.3% | 45.7% | -113.1% | -80.8% |
| ROCE % | -120.1% | -230.1% | -103.7% | -134.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Ayurmaya Capital Management Company, LP | 11.70% | 15.14M | $108.40M |
| 2 | Blackrock Inc. | 6.35% | 8.22M | $58.84M |
| 3 | FMR, LLC | 5.23% | 6.77M | $48.47M |
| 4 | Deep Track Capital, Lp | 4.90% | 6.35M | $45.46M |
| 5 | Samsara BioCapital, LLC | 4.90% | 6.35M | $45.43M |
| 6 | Foresite Capital Management V, LLC | 4.56% | 5.90M | $42.22M |
| 7 | Price (T.Rowe) Associates Inc | 4.02% | 5.20M | $37.23M |
| 8 | venBio Partners LLC | 3.50% | 4.53M | $32.42M |
| 9 | Foresite Capital Management VI LLC | 3.28% | 4.25M | $30.41M |
| 10 | Vanguard Capital Management LLC | 3.26% | 4.22M | $30.18M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ALMS
Alumis snags set of Phase III psoriasis pill victories, but analysts lukewarm on impact
If envudeucitinib gains approval, it will join an increasingly competitive market flanked by drugs like J&J’s Icotyde, Amgen’s Otezla and BMS’ Sotyktu.
Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures
– Results build on ONWARD3 highest complete skin clearance (54% PASI 100) at Week 48, reinforcing envudeucitinib’s potential to become a leading oral therapy for moderate-to-severe plaque psoriasis – Patients switching from placebo or aprem…
Alumis (ALMS) Plans to Advance Envudeucitinib After LUMUS Missed in the Overall Population
Alumis Inc. (NASDAQ:ALMS) reported that the 408-patient Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe systemic lupus erythematosus did not meet its primary or secondary endpoints in the overall population. Envudeucitinib is a…
Alumis to Participate in Upcoming September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced tha…
Is Alumis (ALMS) Overvalued After Its 121% One Year Return?
Alumis stock presents a sharp disconnect between recent share price swings and what broad valuation checks suggest. After a very strong 1 year return, the company now screens as expensive on the wider metrics, even after a steep pullback fo…
Why Alumis (ALMS) Is Down 56.2% After Mixed Phase 2b Lupus Data Spotlight Biomarker Strategy
In early September 2026, Alumis reported that its Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe systemic lupus erythematosus failed to meet primary and secondary endpoints in the overall patient population, despite a favorabl…
ALMS — Frequently Asked Questions
What is the current share price of Alumis Inc. (ALMS)?
As of 2026-10-23 16:27 PDT, Alumis Inc. (ALMS) trades at $6.78 on NasdaqGS. Its 52-week range is $3.95 to $30.30.
What is the market capitalisation of ALMS?
Alumis Inc. (ALMS) has a market capitalisation of $877.57M on NasdaqGS.
What is the P/E ratio of ALMS?
ALMS trades at a trailing price-to-earnings (P/E) ratio of -1.76. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 2.03.
What is the return on equity (ROE) of ALMS?
ALMS has a return on equity (ROE) of -93.65%. Its return on capital employed (ROCE) is -134.01%.
Is ALMS a good stock to buy?
This page provides a data-driven analysis of Alumis Inc. (ALMS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.